A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma

Table 3 Comparison of incidence rates of adverse reactions between the two patient groups

Adverse Reactions	Combination Group	Monotherapy Group	c²	P
Y	5 (12.5%)	7 (14.3%)	0.06	0.81
N	35 (87.5%)	42 (85.7%)

ISSN: 2662-7671